乙酰半胱氨酸泡腾片联合硫酸沙丁胺醇气雾剂对COPD患者稳定期肺功能及血清可溶性髓样细胞触发受体-1的影响

doi:10.3969/j.issn.1006-6233.2019.05.03

Abstract
Figure/Table
References
Related Citation (15)

Download: PDF (1263 KB) HTML (0 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective: To investigate the relationship between acetylcysteine effervescent tablets and salbutamol sulfate aerosol in the stable period lung function and serum soluble myeloid cell trigger receptor-1 (sTREM-1) in patients with chronic obstructive pulmonary disease (COPD). Methods: 82 patients with COPD in our hospital (November 2016-August 2018) were enrolled according to the treatment plan (n=41) and the control group (n=41). On the basis of conventional treatment, the control group was treated with salbutamol sulfate aerosol, and the study group was treated with acetylcysteine effervescent tablets on the basis of the control group for 10 days. The two groups of clinical symptoms (pulmonary signs, wheezing, dyspnea, cough) were relieved, clinical efficacy, lung function indicators before and after treatment [forced vital capacity (FVC), 1st s forced breathing volume (FEV1), FEV1 /FVC] levels, serum sTREM-1 and inflammatory factors [tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6), IL-8] levels, adverse reactions (headache, gastrointestinal tract The incidence of discomfort, itching, vomiting and nausea were counted. Results: ①Clinical symptoms: The lung signs, wheezing, dyspnea, and cough disappeared in the study group were shorter than the control group (P<0.05). ②Clinical efficacy: the total effective rate of the study group was 95.12% (39/41). 78.05% (32/41) in the control group (P<0.05); ③Pulmonary function: The levels of FVC, FEV1, and FEV1/FVC increased after treatment at the end of the two groups, and the study group was higher than the control group (P<0.05); ④serum sTREM-1 and inflammatory factors: serum sTREM-1 and TNF-α, IL-6, IL-8 levels were lower than before treatment, and the study group was lower than the control group ( P<0.05); ⑤Adverse reactions: The incidence of adverse reactions in the study group was 14.63% (6/41) and there was no significant difference between the control group and 9.76% (4/41) (P>0.05). Conclusion: The combination of salbutamol sulfate aerosol and acetylcysteine effervescent tablets in the treatment of patients with stable COPD can effectively shorten the time of clinical symptom relief, reduce serum inflammatory factors and sTREM-1 levels, and reduce the degree of inflammatory response in vivo, inhibit the disease, promote the early recovery of lung function, and does not increase the risk of adverse reactions, and is safe.

Key words： Acetylcysteine effervescent tablets Salbutamol sulfate aerosol COPD Lung function sTREM-1

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors

Cite this article:

URL:

http://www.hbyxzzs.cn/EN/10.3969/j.issn.1006-6233.2019.05.03 OR http://www.hbyxzzs.cn/EN/Y2019/V25/I5/716

[1] 王林梅,齐景宪,冯青青.慢性阻塞性肺疾病急性加重期和稳定期患者血清IL-8、TNF-α及免疫因子的检测[J].郑州大学学报(医学版),2018,53(2):255~258.
[2] 何佳,丁雨红,刘洋.中西医结合治疗慢性阻塞性肺疾病伴呼吸肌疲劳的疗效及对血清白细胞介素6、白细胞介素8的影响[J].中国基层医药,2018,25(20):2635~2637.
[3] 郝文东,王国芳,张彩莲,等.N-乙酰半胱氨酸联合双水平气道正压通气治疗AE-COPD合并Ⅱ型呼吸衰竭的疗效及作用机制研究[J].现代中西医结合杂志,2018,27(7):724~727.
[4] 李立波,卢惠伦.COPD患者血清可溶性髓样细胞触发受体-1与BODE指数的相关性[J].中国临床研究,2015,28(9):1191~1193.
[5] 中华医学会呼吸病学分会慢性阻塞性肺疾病学组.慢性阻塞性肺疾病诊治指南(2007年修订版)[J].中华结核和呼吸杂志,2007,30(8):8~16.
[6] 乔进,施忠,窦志华,等.噻托溴铵联合N-乙酰半胱氨酸治疗慢性阻塞性肺疾病的临床观察[J].中国药房,2015,26(6):757~759.
[7] 邹小新,何花,汪明雪.乙酰半胱氨酸泡腾片与噻托溴铵联用对慢性阻塞性肺疾病患者的临床疗效评价[J].抗感染药学,2015,12(6):946~948.
[8] 李艳艳.纳洛酮联合沙丁胺醇对COPD合并呼吸衰竭患者IL-6、TNF-α和IL-8的影响[J].河北医药,2018,40(7):1068~1070.
[9] 迟玉敏,邸庆国,李敏,等.乙酰半胱氨酸泡腾片治疗慢性阻塞性肺疾病的临床研究[J].中国临床药理学杂志,2018,34(7):763~766.
[10] 胡贵芳,王治国,樊莉莉.乙酰半胱氨酸泡滕片辅助治疗稳定期COPD患者心肺功能、气道重塑的影响[J].海南医学院学报,2017,23(9):1195~1198.
[11] 卢惠伦,游世伦,李立波.可溶性髓样细胞触发受体-1在慢性阻塞性肺疾病患者下呼吸道细菌感染中的诊断价值[J].实用医学杂志,2013,29(13):2123~2125.